Resources|Slideshows|December 24, 2025

Narcolepsy Research Updates

See the latest developments in narcolepsy research.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New AAN Poster Presentation on Alixorexton for Narcolepsy Type 1: Improvement in Disease Severity, Cognitive Functioning, and Fatigue

ByLeah Kuntz

April 20th 2026

Oveporexton Improves Cognition in Narcolepsy Type 1

ByKenneth J. Bender, PharmD, MA

April 2nd 2026

Phase 3 Brilliance Studies Initiated on Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

ByLeah Kuntz

April 1st 2026

NDA Accepted and Priority Review Granted: Oveporexton for Narcolepsy Type 1

ByLeah Kuntz

February 10th 2026

FDA Grants Breakthrough Therapy Designation to Alixorexton for the Treatment of Narcolepsy Type 1

ByLeah Kuntz

January 7th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Narcolepsy Research Updates

Related Content

New AAN Poster Presentation on Alixorexton for Narcolepsy Type 1: Improvement in Disease Severity, Cognitive Functioning, and Fatigue

Oveporexton Improves Cognition in Narcolepsy Type 1

Phase 3 Brilliance Studies Initiated on Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

NDA Accepted and Priority Review Granted: Oveporexton for Narcolepsy Type 1

FDA Grants Breakthrough Therapy Designation to Alixorexton for the Treatment of Narcolepsy Type 1

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

New Positive Phase 2 Topline Data on Elunetirom for the Treatment of Bipolar Depression

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

Suicide Risk Assessment in Patients Denying Suicidal Intent